Print this page    •   Back to Web version of article

Prevention/Epidemiology

Women's Low Adherence to Daily-Dose Products in HIV Prevention Trial Suggest Different Approach Needed, Researchers Say

March 5, 2013

"Results of a major HIV prevention trial suggest that daily use of a product -- whether a vaginal gel or an oral tablet -- does not appear to be the right approach for preventing HIV in young, unmarried African women," a press release from the Microbicide Trials Network reports (3/4). "Adherence among the women in the study was 'very low,' a researcher from the University of Washington said at the Conference on Retroviruses and Opportunistic Infections in Atlanta, where the results were presented," the New York Times writes. "The study, known as VOICE, for Vaginal and Oral Interventions to Control the Epidemic, followed more than 5,000 women in South Africa, Uganda and Zimbabwe" who were given tenofovir gel, oral tenofovir or oral Truvada, and found that, "[a]lthough 95 percent of the women in the study made their monthly clinic visits, and 70 percent said they were using the pills or gel, blood tests suggested that only 25 percent actually were," according to the newspaper (McNeil, 3/4).

"HIV/AIDS experts said the results showed how important a factor human behavior is when devising ways to prevent HIV," Reuters reports. "Clinicians and public health professionals will have to further assess and better understand how to promote and support the high levels of adherence necessary," Jonathan Mermin, an HIV/AIDS prevention expert at the CDC, said, the news agency notes (Herskovitz/Kelland, 3/4). "The VOICE study also found that single women under 25 were the least likely to use the product and the most likely to acquire HIV," a CONRAD press release states (3/4). Mitchell Warren, executive director of AVAC, "said one of the things African women are very concerned about is contraception," VOA News writes, adding, "Future research, therefore, could involve combining birth control pills with an antiretroviral drug" (DeCapua, 3/4). Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Stephen Becker, deputy director of the HIV program at the foundation, says the trial results "provide an opportunity to address fundamental factors that influence prevention product preferences and behaviors. To turn the tide we must stay committed to discovering and developing HIV prevention and treatment tools that those at risk will want and use" (3/4).

Back to other news for March 2013


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.




This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. You can find this article online by typing this address into your Web browser:
http://www.thebodypro.com/content/70736/womens-low-adherence-to-daily-dose-products-in-hiv.html

General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.